Navigation Links
Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract
Date:6/27/2011

to have reached a rapid resolution of the GAO protest so that all parties can continue with the important work of developing smallpox antivirals," said Kenneth I. Moch, President & CEO of Chimerix.  "Chimerix is intensely focused on developing CMX001, for its dual-use potential and as a potent broad spectrum antiviral, to address the threat of smallpox release and the critical needs of immunosuppressed transplant and oncology patients with life-threatening viral infections."

About CMX001

CMX001 is being developed as a potential broad spectrum oral antiviral for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases, including herpes viruses, adenoviruses and orthopox viruses.  The growing body of evidence of CMX001's antiviral activity against all five families of dsDNA viruses that cause morbidity and mortality in humans, including smallpox, has strengthened the compound's potential as a dual-use product prescribed as a traditional pharmaceutical and stockpiled as a biodefense countermeasure. More than 500 patients have been dosed with CMX001 to date in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, preemption and treatment of dsDNA viral diseases.  250 patients have received CMX001 under Emergency Investigational New Drug Applications (EINDs), including for treatment of orthopox viruses.  A significant number of the individuals receiving CMX001 in human testing have been immunocompromised as a result of disease or immunosuppressing therapies associated with stem cell or solid organ transplantation.

Clinical studies of CMX001 include: an ongoing Phase 2 study of the prevention/control of cytomegalovirus (a herpes virus) in adult hematopoietic stem cell transplant patients (CMX001-201); a Phase 2 study currently being initiated for the treatment of adenovirus infection in pediatric and adult hematopoietic stem cell transplant patients (AdV
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chimerix to Present at Two Upcoming Investor Conferences
2. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
3. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
4. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
5. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
6. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
7. Chimerix to Present at Upcoming Investor Conferences
8. Chimerix Initiates Phase 1 Study of CMX157
9. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
10. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
11. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ) ... shares of its Common Stock and Series A Convertible ... The Series A Convertible Preferred Stock is non-voting and ... conversion will be prohibited if, as a result, the ... 4.99% of the Common Stock then outstanding. As part ...
(Date:9/17/2014)... Sept. 17, 2014  MiMedx Group, Inc. (NASDAQ: ... marketer of patent protected regenerative biomaterials and bioimplants ... of another peer-reviewed clinical study.    ... Randomized Controlled Clinical Trial Evaluating the Use of ... and Multi-layer Compression Therapy vs. Multi-layer Compression Therapy ...
(Date:9/17/2014)... & Rockville, MD (PRWEB) September 17, 2014 ... a Small Business Innovation Research (SBIR) grant to support ... The award will provide ITI with approximately $255,000 over ... nuts, a leading cause of food allergy, affect over ... of anaphylaxis behind peanut allergy. Tree nut exposure is ...
(Date:9/17/2014)... 17, 2014 Alternative Fuels Americas, Inc. (AFAI) announced ... Special Purpose Vehicle in partnership with Jatro Greentech, Inc., a ... company. The SPV shall be called AFAI Jatro Green Ethiopia ... majority shareholder. The SPV shall pursue Jatropha planting and biofuels ... Ethiopia . "Although we have ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3
... is pleased to announce that they have acquired ... fully diluted basis. The cash consideration,will be used ... further develop,its technology., Molecular Vision is developing ... that will greatly extend the in-house tools,available to ...
... Inc.,(Nasdaq: VTIV ) today announced that Eran ... Officer, will make a presentation at the,2008 UBS ... which will,be held February 11-13, 2008. The conference ... management presentations and,extensive Q&A opportunities., inVentiv,s presentation ...
... loss of some top,talent, including Lipitor pioneer Dr. ... teaming to help speed research to fight bone ... arthritis and,osteoporosis., Velcura Therapeutics President and CEO ... work with Dr. Sliskovic and International,Discovery Sourcing Consultants, ...
Cached Biology Technology:Acrongenomics Acquires Equity Stake in Molecular Vision 2Acrongenomics Acquires Equity Stake in Molecular Vision 3inVentiv Health to Present at the 2008 UBS Global Healthcare Services Conference 2Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease 2
(Date:9/17/2014)... Kingdom forms a new crime unit designed to fight ... year over horse meat being passed off as beef ... detecting meat adulteration. They describe their approach, which represents ... Journal of Agricultural and Food Chemistry . , Hans-Ulrich ... major global economic problem. But they also say that ...
(Date:9/16/2014)... for Children,s Environmental Health at the Mailman School of ... between childhood asthma and prenatal exposure to two phthalates ... appear online in the journal Environmental Health Perspectives ... pregnancy to higher levels of the chemicals, butylbenzyl phthalate ... and 78 percent increase in risk of developing asthma ...
(Date:9/16/2014)... 2014)More than $100 trillion in cumulative public and ... dioxide (CO2)a 40 percent reduction of urban passenger ... world expands public transportation, walking and cycling in ... the University of California, Davis, and the Institute ... Further, an estimated 1.4 million early deaths could ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5
... University doctoral candidate and a National Park Service researcher ... , J. Judson "Jut" Wynne, an NAU graduate student ... Biological Science Center, and Kyle Voyles from Parashant National ... in northwestern Arizona. , The still-unnamed genus of cave ...
... living on mineral water, the glassy-winged sharpshooter consumes only ... which is feverishly working to prevent the insect's flight ... study published in the June 6 issue of Public ... Institute for Genomic Research (TIGR), the University of Arizona, ...
... approaches to genetic disease, based on cells' own ability to ... at the annual conference of the European Society of Human ... Instead of replacing a faulty gene (commonly referred to as ... therapeutic potential that already exists in human biology. , Professor ...
Cached Biology News:NAU researchers chirping over discovery of new cricket genus 2NAU researchers chirping over discovery of new cricket genus 3Surprising symbiosis: Glassy-winged sharpshooter eats with friends 2Surprising symbiosis: Glassy-winged sharpshooter eats with friends 3'Smart' genetic therapy helps the body to heal itself 2'Smart' genetic therapy helps the body to heal itself 3'Smart' genetic therapy helps the body to heal itself 4
... This personal-sized Thermal Cycler is the ideal ... a full range of PCR applications. ... affordable price. Save lab space without ... software. Industry-Standard PCR Technology You Can ...
... Salmonella typhimurium The genus Salmonella is a ... composed of Gram-negative bacilli that are facultative and ... "H" or flagellar antigen (phase 1 & 2), ... LPS moiety) and the "Vi" or capsular antigen ...
... With 36 mg/L sodium pyruvate, 50 ... 1000 mg/L glucose, calcium chloride, and magnesium ... solution (BSS) in tissue culture is generally ... In 1885, Sydney Ringer developed a solution ...
... micro 1 is a dramatic breakthrough in accurate, ... with 10nL resolution, the micro 1 has unique ... And, the micro 1 never needs re-calibration as ... Screen programming on an LCD Display , Graphical ...
Biology Products: